Stifel has upgraded Alector Inc (NASDAQ: ALEC), noting that while Alzheimer's is a very high risk, the probability of success for AL002 (TREM2 agonist) is above average, and the stock risk/reward is highly attractive ahead of phase 2 data in expected in Q4 2024.
In September, Alector completed enrollment in the INVOKE-2 Phase 2 trial of AL002 for slowing disease progression in individuals with early Alzheimer's disease.
The analyst downgraded ALEC in 2022 after becoming more skeptical about the prospects of AL001 in frontotemporal dementia due to a Full story available on Benzinga.com